Shield Therapeutics PLC Director/PDMR Shareholding (1839J)

TIDMSTX

RNS Number : 1839J

Shield Therapeutics PLC

15 August 2019

Shield Therapeutics plc

("Shield" or the "Company")

Director / PDMR Shareholding

London, UK, 15 August 2019, Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces that James Karis, Chairman of the Company, has acquired 75,000 Ordinary Shares in the Company on 13 August 2019 for consideration of GBP1.78 per Ordinary Share. Following the transaction, Mr Karis holds 161,667 shares, representing 0.001% of the Company's issued share capital.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities/person closely associated 
 a)   Name                                                     James Karis 
     -------------------------------------------------------  -------------------------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------------------------------------------------- 
 a)   Position/status                                          Chairman 
     -------------------------------------------------------  -------------------------------------------------------- 
 b)   Initial notification/ Amendment                          Initial Notification 
     -------------------------------------------------------  -------------------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
     ----------------------------------------------------------------------------------------------------------------- 
 a)   Name                                                     Shield Therapeutics plc 
     -------------------------------------------------------  -------------------------------------------------------- 
 b)   LEI                                                      213800G74QWY15FC3W71 
     -------------------------------------------------------  -------------------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------------------------------------------------------------- 
 a)   Description of the financial instrument, type of         Ordinary shares of 1.5p each in the capital of the 
      instrument                                               Company 
      Identification code                                      ISIN of Ordinary Shares: GB00BYV81293 
     -------------------------------------------------------  -------------------------------------------------------- 
 b)   Nature of the transaction                                Acquisition of Ordinary Shares 
     -------------------------------------------------------  -------------------------------------------------------- 
 c)   Price(s) and volume(s)                                   GBP1.78 per Ordinary Share 
                                                                Volumes: 75,000 
     -------------------------------------------------------  -------------------------------------------------------- 
 d)   Aggregated information                                    75,000 
                                                                 GBP133,500 
        *    Aggregated volume 
 
 
 
        *    Price 
     -------------------------------------------------------  -------------------------------------------------------- 
 e)   Date of the transaction                                  13 August 2019 
     -------------------------------------------------------  -------------------------------------------------------- 
 f)   Place of the transaction                                 London Stock Exchange, AIM Market 
     -------------------------------------------------------  -------------------------------------------------------- 
 

For further information please contact:

 
 Shield Therapeutics plc                                 www.shieldtherapeutics.com 
 Carl Sterritt, Chief Executive 
  Officer                                                       [phone] 
 Tim Watts, Chief Financial Officer 
 
 Nominated Adviser and Joint Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher Golden                              [phone] 
 
 Joint Broker 
 finnCap Ltd                                                    [phone] 
 Geoff Nash /Matt Radley/ Alice 
  Lane 
 
 Financial PR & IR Advisor 
 Walbrook PR                           [phone] or [e-mail] 
                                                  [phone] / +44 (0)7584 
 Paul McManus / Lianne Cawthorne                                            391 303 
 

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R)/Accrufer(R), for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru(R)/Accrufer(R) is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the European Union by Norgine BV, with a US commercialisation partner currently being selected. For more information please visit www.shieldtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the commercial strategy for Feraccru(R)/Accrufer(R). These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with, the Group's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHKELBFKVFFBBQ

(END) Dow Jones Newswires

August 15, 2019 05:17 ET (09:17 GMT)